Categories
Business Health

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced trial results that could bode well for migraine patients

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced trial results Tuesday that could bode well for migraine patients. At the Fifth Congress of the European Academy of Neurology held in Oslo, Norway, Teva presented additional positive results from a Phase 3b exploratory study dubbed FOCUS that evaluated its migraine drug fremanezumab in adults who previously experienced inadequate […]

Categories
Business Health

Merck & Co., Inc. (NYSE:MRK) walking away from nearly $7 million in taxpayer-funded state

Merck & Co., Inc. (NYSE:MRK) is walking away from nearly $7 million in taxpayer-funded state and local incentives aimed at luring to Austin a major technology innovation center operated by the pharmaceutical giant, a project once heralded as the private-sector anchor of a developing medical district around the University of Texas Dell Medical School. The […]

Categories
Health

Pfizer Inc. (NYSE:PFE) announced top-line results from a Phase 4 study

Pfizer Inc. (NYSE:PFE) announced top-line results from a Phase 4 study (CrisADe CARE 1) which showed that crisaborole ointment, 2%, was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), also known as eczema. The data from the trial are supportive of the primary study objective […]

Categories
Health

Neuralstem, Inc. (NASDAQ:CUR) announced publication of manuscript in Stem Cells Translational Medicine

Neuralstem, Inc. (NASDAQ:CUR) announced the publication of a manuscript in Stem Cells Translational Medicine describing the results of an open label Phase 1 clinical trial evaluating the feasibility and safety of transplantation of its lead stem cell asset, NSI-566, for the treatment of motor deficits due to ischemic stroke. The insider ownership percentage is the […]

Categories
Health

Gilead Sciences, Inc. (NASDAQ:GILD) plans to ask FDA to approve arthritis drug this year

Gilead Sciences, Inc. (NASDAQ:GILD)announced afternoon that it plans to ask the Food and Drug Administration to approve an arthritis drug this year. Gilead, in partnership with Galapagos NV GLPG, has been testing a drug known as filgotinib for rheumatoid arthritis, and the latest study results excited investors in March. In a news release Monday, Gilead […]

Categories
Business Health

Active Watch List: PTC Therapeutics, Inc. (NASDAQ:PTCT)

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has completed their review of a proposed indication extension of Translarna™ (ataluren) for the treatment of patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) who are non-ambulatory. While the CHMP adopted a negative opinion of the extension, […]

Categories
Business FEATURED Health

FDA granted approval Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for Soliris

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has been granted approval by the Food and Drug Administration for Soliris. Soliris (eculizumab) is an injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody positive. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), a Healthcare sector firm, traded 1.01 Million shares in last trading session with closing price of $126.11 per share. […]

Categories
Business Headlines Health

FDA approved Pfizer Inc. (NYSE:PFE) oncology biosimilar Zirabev

Pfizer Inc. (NYSE:PFE) said the U.S. Food and Drug Administration has approved its oncology biosimilar Zirabev for the treatment of five types of cancer. The FDA has approved the drug to treat metastatic colorectal cancer, unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and persistent, recurrent […]

Categories
Business Health

Healthcare Gainers: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Odonate Therapeutics, Inc. (NASDAQ:ODT), Kadmon Holdings, Inc. (NYSE:KDMN)

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial (“REVEAL 1”) of VGX-3100, a novel DNA-based immunotherapy being tested to treat cervical dysplasia caused by human papillomavirus (HPV). Left untreated, cervical dysplasia can progress to cervical cancer. If approved, VGX-3100 would be the first immunotherapy […]

Categories
Business Health

Healthcare Mover: Acasti Pharma Inc. (NASDAQ:ACST), Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb Company (NYSE:BMY)

Acasti Pharma Inc. (NASDAQ:ACST) loss for fiscal 2019 expanded from $21.5 million in the prior year to $51.6 million due to higher R&D costs for the TRILOGY Phase 3 program and other financial expenses. The company ended the year with $34.4 million in cash $26.2 million more than than the prior year on the basis of net proceeds from public […]